Preventing and Managing Cardiovascular Toxicities of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Nahla AM Hamed
Additional contact information
Nahla AM Hamed: Faculty of Medicine, Alexandria University, Egypt

Cancer Therapy & Oncology International Journal, 2018, vol. 9, issue 5, 10-12

Abstract: TKIs are small molecules that interfere with the kinase activity. The main TKIs currently used in the treatment of CML are imatinib, nilotinib, dasatinib, bosutinib and ponatinib. Each TKI has a unique side-effect profile, which determines the choice of TKI in a given patient. Recently, TKI-associated vascular adverse events, seen with some of the TKIs, have emerged as one of the most disturbing and poorly understood TKI side effects.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555779.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555779.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:9:y:2018:i:5:p:10-12

DOI: 10.19080/CTOIJ.2018.09.555779

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().